Lehi, UT, March 31, 2026 (GLOBE NEWSWIRE) — Lehi, Utah, March 31, 2026 – CancerVax, Inc., the developer of a step forward common most cancers remedy platform that makes use of the frame’s immune gadget to regard most cancers, nowadays introduced that the preliminary biodistribution find out about of its focused lipid nanoparticle (“LNP”) in mice was once a hit.
Most normal LNPs get trapped within the liver and motive liver toxicity. This can be a primary reason many LNP treatments fail in scientific trials. On this find out about, a big percentage of CancerVax LNPs didn’t seem to amass within the liver in comparison to the bottom standard LNP method. This may occasionally point out systemic movement and distribution to organs and tissues the place most cancers would possibly happen.
The CancerVax platform is designed to harness the frame’s current immunity to locate, mark, and kill most cancers cells with precision. On the core of the platform are customizable nanoparticles that use a unique two-step precision most cancers focused on mechanism.
Detection: The nanoparticles first bind to floor proteins extremely related to the objective most cancers cells (“Marker1”).Activation: As soon as within the most cancers mobile, the nanoparticles free up proprietary “Smart mRNA” payloads which can be simplest activated within the presence of cancer-specific genetic signatures (“Marker2”). Those Sensible mRNAs instruct the most cancers cells to supply proteins related to well-immunized illnesses like measles. This successfully “tricks” the immune gadget into killing most cancers cells as though they had been commonplace illnesses.
Marker1 delivers the nanoparticles to cells expressing the corresponding floor protein and Marker2 selects simplest cancerous cells from that crew to turn on the mRNA healing payload. The use of other combos of Marker1 and Marker2 will goal other cancers to cover them as recognized illnesses and trick the frame into attacking them with energy.
Lately, the Corporate finished its animal-grade Marker1-LNP and was once in a position to continue with its much-anticipated mouse research. The Marker1-LNP was once designed to particularly goal the up to now introduced indications of pancreatic most cancers and liver most cancers.
The primary mouse find out about was once a biodistribution find out about the place Marker1-LNPs had been injected and tracked throughout a lot of tissues. The consequences exceeded the Corporate’s expectancies.
Some step forward effects integrated the next and demonstrated the facility and flexibility of the CancerVax platform:
Systemic Flow of the LNPs: This may permit the CancerVax treatment to achieve many tissues and organs and steer clear of the typical downside of LNP liver accumulation that reasons liver harm and liver failure.Distribution Famous in Many Organs: Spleen, Lung, Liver, Kidney, Intestines, Pancreas, Bladder, Middle, Abdomen, Ovaries/Testes. This encouraging datapoint will permit the Corporate to amplify its analysis program to incorporate many extra most cancers indications for its common most cancers remedy platform. Dosage Reaction: A transparent dose reaction was once noticed on this find out about of 24 mice, with sign depth expanding along administered dose ranges. Importantly, all animals remained wholesome and energetic all over the find out about, suggesting robust tolerability of the Marker1-LNP method.
Dr. Adam Grant, Important Scientist, commented, “We leveraged artificial intelligence to identify an optimal Marker1 for targeting pancreatic and liver cancers. The observed systemic distribution of our Marker1-LNP beyond the target tissues represents an important validation of our platform. While early, these results have exceeded our expectations and support advancement of our dual-marker strategy, where Marker1 and Marker2 are designed to enhance targeting precision and reduce off-target exposure to healthy tissues.”
“This initial success also expands the potential of our platform across multiple indications. By reducing liver accumulation, our targeted LNP approach may enable flexible substitution of Marker1 while maintaining consistent delivery characteristics. I believe one of our current Marker1+Marker2 LNP constructs may already be primed to target colorectal cancers, highlighting the universality of the CancerVax platform.”
“This is a very exciting time for CancerVax,” mentioned Dr. George Katibah, Leader Medical Officer. “We have worked diligently to reach this milestone, and we now have high-quality reagents to support the extensive in vivo studies ahead.”
Dr. Katibah persevered, “This study demonstrated several important advances. First, conjugation of our Marker1 to the LNP preserved the integrity of the core formulation while improving performance. Second, we observed a significant reduction in liver accumulation—a major limitation of conventional LNP therapies. Third, these results further validate our targeted LNP platform as a foundation for precision cancer therapeutics. As we advance through the in vivo phase of our development program, we will conduct additional animal studies to systematically evaluate the safety and efficacy of our novel therapy. These data will be used to support and strengthen our planned Investigational New Drug (IND) application to the FDA for human clinical trials.”
Byron Elton, CEO of CancerVax added, “We would not be here without the work of our amazing science team and the help of our world-class scientific advisors. Over the past year, we have made tremendous progress developing a revolutionary way to treat cancer. The cancer immunotherapy space is very hot right now. In 2025, AbbVie acquired Capstan Therapeutics, a targeted LNP CAR-T therapy company, for $2.1 billion in Phase 1 clinical stage. In 2026, Eli Lilly acquired Orna Therapeutics, a circular RNA and targeted LNP company, for $2.4 billion in preclinical stage. CancerVax is in the targeted LNP, mRNA, cancer immunotherapy and cancer vaccine space. We hope to share our exciting progress with interested strategic partners soon.”
To be told extra concerning the CancerVax platform, please watch the Quick Explainer Video at https://cancervax.com/explainer
About CancerVax
CancerVax is a pre-clinical biotech corporate growing a unique Common Most cancers Remedy platform that can be customizable, as an injection, to regard many varieties of most cancers. Our cutting edge means DETECTS, MARKS, and KILLS simplest most cancers cells. By way of making most cancers cells appear to be well-immunized commonplace illnesses, reminiscent of measles or chickenpox, we intend to make use of the frame’s herbal immune gadget to simply kill the most cancers cells. We sit up for the day when treating most cancers can be so simple as getting a shot — a greater solution to combat most cancers. To be told extra, please discuss with www.CancerVax.com
Ahead-Taking a look Statements
This press free up would possibly comprise “forward-looking statements” inside the which means of the protected harbor provisions of the U.S. Personal Securities Litigation Reform Act of 1995. Ahead-looking statements are neither ancient information nor assurances of long run efficiency. As a substitute, they’re primarily based simplest on our present ideals, expectancies, and assumptions relating to the way forward for our trade, plans and techniques, projections, expected occasions and traits, the economic system, and different long run prerequisites. As a result of forward-looking statements relate to the longer term, they’re matter to inherent uncertainties, dangers, and adjustments in cases which can be tricky to are expecting, lots of that are outdoor our keep watch over. Our precise effects and monetary situation would possibly range materially from the ones within the forward-looking statements. Subsequently, you will have to now not depend on any of those forward-looking statements. Any forward-looking commentary made via us on this free up is primarily based simplest on knowledge lately to be had to us and speaks simplest as of the date it’s made. We adopt no legal responsibility to publicly replace any forward-looking commentary, whether or not written or oral, that can be made now and again, whether or not because of new knowledge, long run tendencies, or in a different way.
